Table 5. Proportions and odds ratio of anti-angiogenic diseases in relation to ONJ without consideration of bisphosphonates.
| Anti-angiogenic disease | Group 1A and 2A (n=64) | Group 1B and 2B (n=71) | Odds ratio | P-value | ||
|---|---|---|---|---|---|---|
| Yes | No | Yes | No | |||
| DM | 12 (18.8) | 52 (81.3) | 11 (15.5) | 60 (84.5) | 1.26 | 0.616 |
| Hypertension | 32 (50.0) | 32 (50.0) | 33 (46.5) | 38 (53.5) | 1.15 | 0.683 |
| RA | 8 (12.5) | 56 (87.5) | 3 (4.2) | 68 (95.8) | 3.23 | 0.094 |
| Hyperlipidemia | 12 (18.8) | 52 (81.3) | 7 (9.9) | 64 (90.1) | 2.10 | 0.144 |
| More than 1 disease | 47 (73.4) | 17 (26.6) | 37 (52.1) | 34 (47.9) | 2.54 | 0.012 |
(ONJ: osteonecrosis of the jaw, DM: diabetes mellitus type II, RA: rheumatoid arthritis, More than 1 disease: existence of more than one of the antiangiogenic diseases above)
Group 1A: bisphosphonate-related osteonecrosis of the jaw (BRONJ) group, Group 2A: ONJ group, Group 1B: non-BRONJ group, Group 2B: control group.